Table 3.
Frequency and Rates of Outcomes during the Baseline and Intervention Periods, According to Study Group.*
| Outcome | Group 1 | Group 2 | Group 3 | |||
|---|---|---|---|---|---|---|
| Baseline | Intervention | Baseline | Intervention | Baseline | Intervention | |
| no. of events (crude rate per 1000 patient-days) | ||||||
| MRSA clinical cultures | 216 (3.4) | 279 (3.2) | 245 (4.3) | 301 (3.2) | 240 (3.4) | 217 (2.1) |
| Bloodstream infection | ||||||
| MRSA | 37 (0.6) | 63 (0.7) | 31 (0.5) | 61 (0.6) | 46 (0.6) | 48 (0.5) |
| Any pathogen† | 265 (4.2) | 360 (4.1) | 273 (4.8) | 341 (3.7) | 412 (6.1) | 356 (3.6) |
| Gram-positive organism | 165 (2.6) | 228 (2.6) | 159 (2.8) | 203 (2.2) | 253 (3.7) | 187 (1.9) |
| Skin commensal organism | 50 (0.8) | 55 (0.6) | 49 (0.9) | 46 (0.5) | 120 (1.8) | 38 (0.4) |
| Noncommensal organism | 115 (1.8) | 173 (2.0) | 110 (1.9) | 157 (1.7) | 133 (2.0) | 149 (1.5) |
| Gram-negative organism | 62 (1.0) | 83 (0.9) | 58 (1.0) | 75 (0.8) | 100 (1.5) | 107 (1.1) |
| Candida species | 38 (0.6) | 49 (0.6) | 56 (1.0) | 63 (0.7) | 59 (0.9) | 62 (0.6) |
*
Provided rates are crude rates, defined as the number of events per 1000 ICU-attributable patient-days at risk for the event. Patient-days after each event were excluded from the analysis; thus, denominators are different for each cell and are not included.
†
The distribution of all bloodstream events is based on the first eligible event from any pathogen per patient. For example, a patient with a first ICU-associated bloodstream infection (due to a gram-positive organism) followed by a second ICU-associated bloodstream infection (due to a gram-negative organism) would be counted only in the listing for gram-positive organisms.